Profile
Andrew John Scott Walton-Green is currently the Chairman at Biosceptre (Aust) Pty Ltd. and Biosceptre International Ltd. He is also a Director at Project Better Energy Ltd. In the past, he served as the Chief Executive Officer at Gresham Technologies Plc from 2000 to 2010.
Andrew Walton-Green active positions
| Companies | Position | Start |
|---|---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops oncology immunotherapies for applications in the diagnosis and treatment of cancer | Chairman | 20/12/2018 |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Operates as biotechnology company which develops cancer therapeutics and multiple drugs | Chairman | 01/12/2014 |
Project Better Energy Ltd.
Project Better Energy Ltd. Electric UtilitiesUtilities Engages in generating electric power | Director/Board Member | 31/03/2014 |
Former positions of Andrew Walton-Green
| Companies | Position | End |
|---|---|---|
| GRESHAM TECHNOLOGIES | President | 28/04/2010 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Gresham Technologies Plc
Gresham Technologies Plc Information Technology ServicesTechnology Services Provides data integrity, reconciliation and enterprise data automation solutions for global financial institutions | Technology Services |
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops oncology immunotherapies for applications in the diagnosis and treatment of cancer | Health Technology |
Project Better Energy Ltd.
Project Better Energy Ltd. Electric UtilitiesUtilities Engages in generating electric power | Utilities |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Operates as biotechnology company which develops cancer therapeutics and multiple drugs | Health Technology |
- Stock Market
- Insiders
- Andrew Walton-Green
















